Clinical trials regulation--how Canada compares

Shuchman, Miriam
September 2008
CMAJ: Canadian Medical Association Journal;9/23/2008, Vol. 179 Issue 7, p635
Academic Journal
journal article
The article reports on the safety of clinical trials after the incidence of a 48-year-old man with no history of cardiac problems suffered two heart attacks and died during a testing of a new drug. The Medicine and Healthcare Products Regulatory Agency of Great Britain conducted an investigation regarding the anomalous death. Due to the incident, Great Britain and U.S. were forced to reform their system of clinical trials. For two years, Health Canada has been reviewing its clinical trials regulatory framework but restructuring proposals for the system have been reported. INSET: Canada lags the United States in transparency of clinical....


Related Articles

  • Safeguarding clinical trial participants at another level.  // Australasian Biotechnology;Sep2008, Vol. 18 Issue 3, p76 

    The article reports on a proposal from the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain for the establishment of a voluntary accreditation scheme for units that conduct phase 1 trials in the country. The scheme is intended to maximise subject safety and to crate...

  • Press One for Safety. Meinert, Lawrence; Ward, Hal // Applied Clinical Trials;Sep2007, Vol. 16 Issue 9, p46 

    The article focuses on the concept that can be used by clinical trials professionals in determining the total number of exposed patients in clinical trials. The author points out the use of an Interactive Voice Response (IVR) systems which will improve the practitioner's understanding of adverse...

  • Procedures required of sponsors prior to embarking on clinical trials in humans.  // Clinical Risk;May2010, Vol. 16 Issue 3, p88 

    When embarking on a clinical trial of an investigational medicinal product (IMP) for the first time in humans, the risks associated with the administration of the compound must be identified and mitigated accordingly. This article outlines some of the guidance sponsors should consider when...

  • Use of herbal medicines. Newson, Louise // GP: General Practitioner;3/16/2007, p46 

    The article reports on the status of herbal medicine in Great Britain. Legally, herbal products are classified as food supplements and are widely available from health food shops and chemists. For most herbal treatments trials of efficacy are lacking. In Great Britain, the Medicines and...

  • Agency criticises drug trial. Day, Micahel // BMJ: British Medical Journal (International Edition);6/3/2006, Vol. 332 Issue 7553, p1290 

    The article discusses a final government report of an investigation into the failure of a drug trial that left six volunteers in a London hospital. The report concluded that the failure of the trial cannot be blamed on the manufacturing process or the way the drug was administered. It criticized...

  • HIV drugs made in tobacco. Fox, Jeffrey L // Nature Biotechnology;Oct2011, Vol. 29 Issue 10, p852 

    The article reports that the British Medicines and Healthcare Products Regulatory Agency has approved the phase 1 clinical trial of Pharma-Planta's human monoclonal antibody made in genetically modified tobacco plants for preventing human immunodefiency virus (HIV) spread between sexual partners.

  • Health Canada issues foreign product alerts.  // Reactions Weekly;5/10/2008, Issue 1201, p3 

    The article reports on the warning of Health Canada regarding the use of Tian Li or Xian Zhi Wei II due to their adverse effects. Great Britain's Medicines and Healthcare products Regulatory Agency (MHRA) states that Tian Li is said to have tadalafil and hydroxyhomosildenafil which are not...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;1/20/2007, Issue 1135, p2 

    The article offers regulatory news on pharmacology. A Foreign Product Alert was issued by Health Canada to warn that Qing Zhi along with one unlabelled product were found to be adulterated with sibutramine. The British Medicines & Healthcare Products Regulatory Agency is warning against the use...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;7/26/2008, Issue 1212, p2 

    This section offers news briefs on issues related to pharmacovigilance. Neurogen Corp. has suspended a clinical trial investigating the treatment of insomnia with a bilayer tablet formulation of adipiplon due to a higher rate of unwanted next day effects. The Canadian government is planning to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics